Butchered by Healthcare

By Dr. Robert Yoho – 50 Q&As – Unbekoming Book Summary

In "Butchered by Healthcare," Dr. Robert Yoho delivers a powerful exposé of the American medical system that will fundamentally change how you view modern medicine. Drawing on decades of experience as a physician, Yoho methodically dismantles the myths of a healthcare system dedicated to healing, revealing instead a profit-driven machine where pharmaceutical companies, hospitals, device manufacturers, and even doctors themselves often prioritize financial gain over patient welfare. This eye-opening work meticulously documents how half of all medical treatments lack scientific support, how drug companies manipulate research, how unnecessary procedures are routinely performed, and how the entire enterprise has been corrupted by the relentless pursuit of profit.

I've learned so much from Dr. Yoho over the last few years and am grateful for all the work he has done to help people understand the dangers of Cartel Medicine. As a primary voice and source in teaching people about the benefits of chlorine dioxide, he continues to challenge conventional wisdom and expose treatments that work but remain suppressed by the profit-focused medical establishment. His courage in speaking truth to power serves as an essential counterbalance to the overwhelming influence of corporate healthcare interests.

With thanks to Dr. Robert Yoho.

Butchered by "Healthcare" ebook is HERE, and an interview about it is HERE. This still sells 100 copies a month. The link to go straight to the Amazon review page is HERE.

Related Posts

Hormone Secrets: Feel Great and Age Well using the Bio-Identicals

Aspirin vs Tylenol - Lies are Unbekoming

Deep Dive Conversation Library (Bonus for Paid Subscribers)

This deep dive is based on the book:

Discussion No.58:

24 key insights from “Butchered by Healthcare”

Thank you for your support.

Analogy

Imagine you take your car to a repair shop, but instead of a traditional mechanic, you encounter a bizarrely corrupted system:

The shop doesn't tell you their prices until after the work is done. They charge you $500 for each inspection, regardless of whether they find anything wrong. A committee of mechanics - all paid by auto parts manufacturers - creates "guidelines" requiring everyone to replace their transmission fluid every 1,000 miles. The mechanics get a percentage of the parts' cost, so they push the most expensive options.

When you question a repair, they show you research papers - written by parts manufacturers but published under mechanics' names - claiming that frequent part replacement extends vehicle life. The government agency responsible for auto safety gets most of its funding from car companies and rarely investigates problems. If parts fail catastrophically, the manufacturers pay fines but admit no wrongdoing and keep selling the same parts.

The mechanics attend educational seminars at luxury resorts, paid for by parts manufacturers, where they learn about newly invented car problems that require expensive treatments. They genuinely believe they're helping, even as they perform unnecessary repairs that sometimes damage cars. When repairs don't work, they blame the car's age or the owner's driving habits rather than questioning their approach.

Most tellingly, mechanics in this system would make the most money by keeping cars perpetually in need of repair rather than fixing them properly. The entire system would be oriented toward generating revenue rather than maintaining healthy vehicles.

This is precisely how our healthcare system operates - a maintenance system corrupted into a profit-generating machine that often causes more harm than good while consuming ever-increasing resources. Just as you wouldn't want your car maintained in such a system, we shouldn't accept this approach to maintaining human health.

12-point summary

1. Healthcare System Fundamentals: The American healthcare system consumes $4 trillion annually (20% of GDP) while delivering worse outcomes than other developed nations. Insurance companies and administrative costs consume 30-40% of all spending before any care is delivered.

2. Evidence-Based Reality: Only about 35% of current medical practices have solid scientific evidence supporting their effectiveness. Another 15% are harmful, while 50% are of unknown usefulness. This creates a system where patients frequently receive unnecessary or harmful treatments.

3. Pharmaceutical Industry Corruption: Drug companies routinely manipulate research, conceal negative data, and pay enormous settlements for criminal behavior while treating these penalties as a cost of doing business. They spend more on marketing than research and use sophisticated influence techniques to drive prescribing.

4. Medical Literature Compromise: Medical journals have become marketing tools for industry, with up to 70% of their revenue coming from drug companies. Most published research is ghostwritten by industry contractors and published under academic physicians' names to provide credibility.

5. Device Industry Problems: Medical devices face minimal testing requirements before approval, with 95% approved automatically through the 510(k) process. This leads to frequent problems with inadequately tested devices, while legal protections shield manufacturers from consequences.

6. Psychiatric Medication Crisis: One in six Americans takes psychiatric drugs despite limited evidence of benefit and significant evidence of harm. These medications often create long-term dependence while failing to address underlying issues.

7. Cancer Treatment Reality: Most modern cancer treatments offer remarkably modest benefits despite enormous costs. The average survival benefit for new drugs is just 2.1 months, while costs frequently exceed $100,000 per patient annually.

8. Screening Program Failures: Most cancer screening programs, including mammography and routine colonoscopy, have failed to demonstrate improvements in overall survival while generating significant harms through overdiagnosis and overtreatment.

9. Hospital Billing Practices: Hospitals use complex billing strategies to maximize revenue, including inflated chargemaster prices, facility fees, and out-of-network providers. This creates a system where even insured patients face financial ruin from medical bills.

10. FDA Capture: The FDA has been captured by industry through user fees that provide most of its funding. This has transformed it from an independent regulator into an organization that views industry as its client.

11. Doctor Incentives: The fee-for-service system creates perverse incentives for doctors to provide more services regardless of benefit. Industry influence through gifts, payments, and marketing affects prescribing patterns even when doctors believe they remain objective.

12. Reform Requirements: Meaningful reform requires criminalizing currently accepted practices like disease mongering and data concealment, eliminating conflicts of interest, restructuring the patent system, and moving away from fee-for-service payment models.

50 Questions & Answers

1. Why does American healthcare cost twice as much as other developed nations while delivering worse outcomes?

The American healthcare system has evolved into a complex web of profit-driven entities that extract enormous amounts of money before any care is delivered. Insurance companies consume about 20% of all healthcare spending just for administration and profits, while hospitals, doctors, and other providers spend another 25-40% on their own administrative costs. When combined with the expenses of billing, collections, and other overhead, as much as 75% of healthcare spending may be consumed before patient care begins.

This system encourages overuse of expensive tests, procedures, and medications since third-party payment removes cost consciousness from both doctors and patients. With insurance and government programs paying the bills, there are no market forces to control costs. The result is that the U.S. spends $4 trillion annually on healthcare, nearly 20% of GDP, while having worse health outcomes than other developed nations who spend half as much per capita.

2. How do insurance companies contribute to healthcare waste and inefficiency?

Insurance companies operate as middlemen who extract substantial profits while adding layers of bureaucracy and waste to healthcare delivery. They consume roughly 20% of all healthcare spending through their administration, marketing, executive salaries, and profit margins. This "medical loss ratio" means that only 80 cents of every premium dollar actually goes toward patient care, with the rest funding the insurance industry's overhead.

Rather than controlling costs, insurance companies simply pass increases on to employers and patients through higher premiums. They have little incentive to reduce overall spending since their profits are a percentage of total costs. The complexity of insurance billing and requirements forces providers to maintain expensive administrative staff just to get paid, creating even more waste. The system has become so byzantine that providers often spend more time on paperwork than patient care.

3. What percentage of healthcare spending is consumed by administrative costs?

Administrative costs consume between 30-31% of total U.S. healthcare spending according to recent studies in the Annals of Internal Medicine and estimates by healthcare economists. Insurance companies take about 20% off the top for their administration and profits. Hospitals then spend another 25% or more on their own administrative costs, while physician practices devote substantial resources to billing and insurance-related expenses.

When all sources of administrative overhead are combined - including insurance companies, hospitals, physician practices, pharmaceutical benefit managers, and other entities - the total administrative burden likely exceeds 30% of healthcare spending. This amounts to hundreds of billions of dollars annually that could otherwise go toward actual patient care. Other developed nations typically spend less than half this amount on healthcare administration.

4. How has the fee-for-service model impacted healthcare delivery?

Fee-for-service reimbursement creates perverse incentives by paying providers for each service, test, or procedure rather than for keeping patients healthy. This encourages physicians and hospitals to maximize the volume of services regardless of necessity or benefit. The system rewards quantity over quality and complexity over simplicity. Providers are incentivized to perform unnecessary tests and procedures since they get paid more for doing more.

The model has led to widespread overuse of medical services as providers chase revenue rather than optimal outcomes. Unnecessary surgeries, excessive testing, and overuse of expensive medications have become commonplace. Since third-party payers handle most costs, neither doctors nor patients have incentives to consider cost-effectiveness. The result is a system that generates enormous waste while often delivering suboptimal care.

5. What role does Kaiser Permanente play as an alternative healthcare model?

Kaiser Permanente represents an integrated model that combines insurance, hospitals, and physicians into a coordinated system focused on cost-effective care. By putting doctors on salary rather than fee-for-service, Kaiser removes incentives for unnecessary care. Their integrated structure allows them to focus on prevention and appropriate care rather than maximizing billable services. With $84.5 billion in revenue and 12.2 million patients, they demonstrate that alternative models can work at scale.

Kaiser's approach produces reasonable quality metrics while controlling costs better than traditional fee-for-service systems. Their doctors have objectivity in medical decisions since their income isn't tied to ordering more tests and procedures. While not perfect, Kaiser shows how aligning incentives and integrating care delivery can potentially improve both efficiency and outcomes compared to the fragmented traditional system.

6. How do pharmaceutical companies manipulate drug trials and research?

Pharmaceutical companies routinely manipulate clinical trials to make their drugs appear more effective than they are. They use techniques like selective reporting of positive results while burying negative studies, choosing inappropriate comparison groups, using surrogate endpoints instead of meaningful outcomes, and even outright data falsification. Contract research organizations are paid to produce favorable results rather than objective science. The companies then use ghostwriters to prepare journal articles promoting their drugs.

The manipulation extends to every aspect of the research process. Companies cherry-pick data, switch patients between study groups, hide adverse events, and use statistical tricks to manufacture positive results. When studies show their drugs don't work or cause harm, the data is often concealed as "proprietary information." Even when manipulation is discovered, it's usually treated as a cost of doing business rather than criminal fraud.

7. What are the most significant criminal settlements paid by pharmaceutical companies?

GlaxoSmithKline paid a record $3 billion settlement in 2012 after pleading guilty to federal criminal charges related to illegal marketing of medications, concealing safety data, and paying kickbacks to doctors. The company had promoted unapproved uses of drugs, lied about safety in medical journals, and illegally marketed drugs to children. Despite the massive fine, this represented only about a month's revenue for GSK.

Pfizer paid $2.3 billion in 2009 for illegal marketing of drugs like Bextra, their fourth major settlement in a decade. According to a company whistleblower, "the whole culture of Pfizer is driven by sales." The pattern repeats across the industry - companies rack up billions in criminal settlements but treat them as a cost of doing business since their revenues dwarf the penalties. No executives typically face jail time despite documented criminal behavior.

8. How do drug companies influence physician prescribing habits?

Drug companies employ sophisticated influence techniques targeting doctors through gifts, meals, speaking fees, and research funding. They use the "three F's of sales" - food, flattery, and friendship - to build relationships with physicians. Even small gifts like meals have been shown to significantly increase prescribing of promoted drugs. Doctors who accept industry money prescribe brand-name medications at twice the rate of those who don't.

The industry maintains one sales representative for every five doctors in the U.S. They identify high-prescribing doctors as "whales" and lavish them with attention and perks. Some consultants receive hundreds of thousands of dollars annually in speaking fees and other payments. While doctors believe they remain objective, research shows that even minor gifts significantly impact prescribing patterns. The companies wouldn't spend billions on marketing to physicians if it didn't work.

9. What is disease mongering and how does it drive pharmaceutical profits?

Disease mongering involves expanding the definitions of diseases and promoting new conditions to sell more drugs. Companies work with prominent physicians to create more inclusive diagnostic criteria, turning normal variations into diseases requiring treatment. For example, the diabetes definition was changed from a fasting blood sugar of 140 to 126, instantly creating millions of new patients needing medication. Similar expansions occurred with blood pressure, cholesterol, and other conditions.

The strategy involves promoting awareness of conditions through advocacy groups and direct-to-consumer advertising while simultaneously lowering diagnostic thresholds. Normal experiences like sadness, anxiety, or restlessness get reframed as medical conditions requiring treatment. The result is that more than half of Americans now qualify as having some condition requiring medication. This expansion of disease definitions has been a key driver of pharmaceutical industry profits.

10. How do patent laws and exclusivity rights affect drug pricing?

Patent laws give drug companies 20-year monopolies on new medications, allowing them to charge whatever prices they want without competition. The companies exploit this through various techniques to extend patents, including filing hundreds of follow-on patents for minor changes, suing generic manufacturers to trigger automatic delays, and even paying generic makers to delay introducing competing products. These tactics keep prices high long after the original patent should have expired.

The impact on pricing is dramatic. Companies routinely charge hundreds or thousands of dollars monthly for drugs that cost only dollars to produce. When patents expire and generic competition arrives, prices typically fall by 80% or more. The industry claims high prices are needed to fund research, but marketing expenses typically far exceed research costs. The patent system has become a tool for maintaining artificial monopolies rather than incentivizing true innovation.

11. What percentage of current medical treatments are scientifically proven to work?

According to multiple sources including the British Medical Journal Clinical Evidence survey, only about 35% of medical practices have solid scientific evidence supporting their effectiveness. Another 15% are actually harmful, while 50% are of unknown usefulness. The Congressional Budget Office estimates that 30% of medical care is unnecessary, while other authorities using the Milliman Health Waste Calculator suggest useless therapeutic activities comprise 48% of care.

This stark reality stems from several factors, including inadequate research, industry influence on studies, and the continued use of treatments based on tradition rather than evidence. The Scientific American noted that experts largely agree that "less than 20 percent of what physicians do has solid research to support it," though this is rarely discussed publicly. Even when studies show treatments don't work, they often remain in use due to financial incentives and institutional inertia.

12. Why are coronary stents and bypass surgeries still commonly performed despite evidence they don't work?

Coronary artery bypass grafting (CABG) surgery has been proven to extend life only in the tiny fraction of patients (about 3%) who have severe left main coronary artery blockage. For all other patients, the surgery offers no survival benefit compared to medical therapy alone. Despite this, hundreds of thousands of these surgeries are performed annually, with significant risks including death in 2-9% of cases and brain damage in roughly one-third of survivors.

Similarly, angioplasty and stents have been shown through multiple studies, including the ORBITA trial using sham surgery controls, to provide no benefit for stable heart disease. Yet these procedures continue to be performed hundreds of thousands of times annually at great expense. The procedures persist because they generate enormous revenue for hospitals and physicians, while the compelling mechanical logic of "fixing blockages" makes intuitive sense to both doctors and patients, even though the science shows they don't improve outcomes.

13. What's wrong with the current approach to back pain treatment?

The current approach to back pain represents a $100 billion annual industry built on treatments that scientific evidence shows don't work. This includes surgery, chiropractic care, injections, ultrasound, electrical stimulation, and various other therapies. Studies have repeatedly shown that none of these interventions improve long-term outcomes compared to no treatment. Spinal fusion surgery, which costs up to $100,000 per procedure, is particularly problematic as only 15% of patients ever return to work after the operation.

The only intervention consistently shown to help back pain is graduated exercise, yet the medical system continues to promote expensive, invasive treatments. The industry creates chronic dependency on providers and procedures while often making the underlying problem worse. Many patients get trapped in a cycle of ongoing treatments, opioid medications, and surgeries that provide no lasting benefit but generate reliable revenue for providers.

14. How effective are cancer treatments in extending life?

Most modern cancer treatments offer remarkably modest benefits despite their enormous costs. A comprehensive literature review found that chemotherapy added only 2.1% to the five-year survival rate for U.S. adults with cancer. Even the newest, most expensive drugs approved between 2014-2016 provided an average survival benefit of just 2.1 months compared to older treatments. For most common cancers, including lung, breast, colon, and prostate, survival improvements are measured in months or weeks, if they exist at all.

The reality of cancer treatment effectiveness is routinely obscured by statistical manipulation and marketing. Drug companies promote "progression-free survival" rather than actual survival benefits, and use relative rather than absolute risk statistics to make tiny benefits appear more significant. Meanwhile, these treatments often cost hundreds of thousands of dollars and can severely impact quality of life. The American Society of Clinical Oncology now considers a 2.5-month life extension a successful outcome for new chemotherapy drugs.

15. Why are psychiatric medications so widely prescribed despite limited evidence of benefit?

Psychiatric medications represent a massive marketing triumph that has transformed normal human emotions and experiences into medical conditions requiring treatment. Through aggressive promotion and disease mongering, the industry has convinced doctors and the public that common experiences like anxiety, sadness, and restlessness require medication. This has led to one in six Americans taking psychiatric drugs, despite limited evidence of benefit and significant evidence of harm.

Studies show that antidepressants barely outperform placebos, while antipsychotics can cause permanent brain damage and reduce life expectancy by up to 20 years. Yet these drugs generate enormous profits, leading to continued expansion of psychiatric diagnoses and prescribing. The medications are also extremely difficult to stop once started, creating lifelong customers. The industry has successfully medicalized normal human variation while downplaying or concealing evidence of harm.

16. How are medical devices approved and regulated?

Medical devices face far less scrutiny than drugs in the approval process, with 95% approved automatically through the 510(k) process if they are "substantially similar" to existing devices. This means most devices reach the market with minimal testing, often based on comparison to previously approved devices that themselves may never have been properly studied. The FDA typically requires only small studies of tens or hundreds of patients rather than the thousands required for drug approval.

The result is frequent problems with devices that were inadequately tested before widespread use. The FDA recalls about 1,100 devices annually, but oversight is minimal due to the agency's limited resources and heavy industry influence. Most significantly, a Supreme Court decision (Riegel v. Medtronic) largely shields device makers from lawsuits if the FDA approved their product, removing a key incentive for safety.

17. What are the most problematic medical devices described in the book?

Several medical devices have caused widespread harm while generating massive profits. Surgical mesh for pelvic repair led to severe complications including chronic pain and tissue damage, yet was widely used before being restricted. The Essure sterilization device caused numerous complications requiring surgical removal before being withdrawn from the market. Vagal nerve stimulators were approved despite FDA scientists' unanimous opposition and continue to be promoted for dozens of conditions despite limited evidence of benefit.

Inferior vena cava filters, metal implants meant to prevent blood clots, have been shown to cause more harm than good in many patients. Joint implants using metal-on-metal designs caused widespread problems with metal poisoning. Yet in most cases, manufacturers faced few consequences due to legal protections, while marketing of new devices continues with minimal testing requirements. The focus remains on getting devices to market quickly rather than ensuring safety and effectiveness.

18. Why is device company oversight more lenient than drug oversight?

Device company oversight evolved differently from drug regulation, which was strengthened after the thalidomide disaster in the 1960s. Devices that existed before regulation were "grandfathered" in without testing, and new devices can be approved based on similarity to these older devices rather than independent safety studies. The device industry has successfully lobbied to maintain this lenient system, arguing that more stringent requirements would slow innovation.

Additionally, the FDA's device division receives most of its funding directly from industry user fees, creating a conflict of interest that encourages rapid approvals. The agency has limited resources to monitor the thousands of device manufacturers worldwide, and foreign inspections are especially problematic. When problems are found, the agency typically allows voluntary recalls rather than forcing withdrawals, and criminal penalties are rare even for serious violations.

19. How do device manufacturers influence surgeons?

Device manufacturers use many of the same influence techniques as drug companies, providing surgeons with consulting fees, research grants, royalty agreements and other payments that can amount to millions of dollars annually. They pay surgeons to promote their products at medical conferences and train other surgeons in using their devices. Some surgeons receive such large payments that they effectively become marketing agents for the companies while maintaining the appearance of independent medical practice.

The companies also provide hospitals with expensive equipment in exchange for commitments to use their devices, and they cultivate relationships with administrators who make purchasing decisions. The result is that device selection often reflects marketing success rather than clinical evidence. Even when devices are shown to have problems, surgeons who receive company payments often continue using them, highlighting how financial relationships can override medical judgment.

20. What reforms are needed in medical device regulation?

Fundamental reforms are needed in device regulation, starting with elimination of the 510(k) process that allows approval based on similarity to existing devices. All new devices should require actual safety and effectiveness studies before approval, similar to drug requirements. The FDA needs greater independence from industry influence, including alternative funding sources besides user fees. Enhanced post-market surveillance is also essential to identify problems quickly once devices are in use.

Legal reforms are also needed to remove inappropriate protections for device makers and allow injured patients to seek compensation through the courts. This would create proper incentives for safety. Additionally, payments to physicians from device makers should be strictly limited or banned to prevent conflicts of interest from influencing device selection. The focus must shift from rapid market access to ensuring safety and effectiveness through proper scientific study.

21. How do pharmaceutical companies influence medical research?

Pharmaceutical companies have gained nearly complete control over medical research through their funding and manipulation of the entire research process. They design studies specifically to make their drugs look effective, using contract research organizations that are paid to produce positive results rather than objective science. When studies show negative results, they simply bury them and never publish the data. The companies then employ ghostwriters to prepare journal articles promoting their interpretation of the research, paying prominent physicians to add their names as authors.

The corruption extends through every level of the research enterprise. Companies select which patients to include or exclude, choose inappropriate comparison groups, use misleading endpoints, and manipulate statistics to manufacture positive results. Medical journals, which receive up to 70% of their revenue from drug company reprints and advertising, routinely publish these ghostwritten articles under the names of academic physicians. The result is a medical literature that has become an extension of pharmaceutical marketing rather than objective science.

22. What role do medical journals play in healthcare corruption?

Medical journals have become primarily marketing vehicles for the pharmaceutical industry rather than independent scientific publications. Up to 70% of major medical journals' revenue comes directly from drug companies through advertising and bulk purchases of reprints used for marketing. This financial dependence has led journals to routinely publish ghostwritten articles promoting industry products while rarely questioning or investigating industry claims. The editors themselves often receive substantial payments from drug companies, creating obvious conflicts of interest.

Even the most prestigious journals like the New England Journal of Medicine and The Lancet have been compromised by industry influence. Their former editors have publicly stated that medical journals have become "information laundering operations" for pharmaceutical companies. The peer review process provides little protection since most reviewers have their own industry ties. The result is a medical literature that doctors rely on for clinical decisions but which has been thoroughly corrupted by commercial interests.

23. How are medical guidelines compromised by industry influence?

Clinical practice guidelines, which essentially dictate how doctors should treat various conditions, are routinely written by physicians with extensive financial ties to pharmaceutical companies. Studies show that up to 80% of guideline authors have conflicts of interest, with many serving on drug company speakers' bureaus or advisory boards. These guidelines often recommend extensive use of expensive medications while downplaying risks or alternatives. The companies then use these guidelines to promote their products and pressure doctors to prescribe them.

For example, guidelines for conditions like high blood pressure, diabetes, and high cholesterol have consistently lowered diagnostic thresholds and expanded treatment recommendations in ways that benefit drug companies. Authors of these guidelines typically have multiple financial relationships with companies that stand to profit from expanded treatment recommendations. Yet these guidelines are presented as objective scientific documents rather than what they often are - marketing tools created by physicians with significant industry ties.

24. Why do doctors continue providing treatments they know don't work?

Physicians face multiple pressures that lead them to continue providing treatments despite evidence they don't work. The fee-for-service system rewards them financially for doing more rather than doing what's best. Many doctors have invested years in learning particular procedures and built practices around them, making it psychologically and financially difficult to stop. There's also fear of lawsuits if they don't provide treatments that are considered "standard of care," even if evidence shows they're ineffective.

Additionally, both doctors and patients often prefer action over inaction, even when the evidence suggests doing nothing would be better. The compelling mechanical logic of many treatments (like "fixing" blocked arteries) makes intuitive sense even when studies show they don't improve outcomes. Finally, doctors are human and subject to the same influence techniques as everyone else - gifts, relationships with industry representatives, and marketing can affect their judgment even when they believe they remain objective.

25. How has medical education been corrupted by industry?

Medical education has been systematically compromised by industry influence at every level. Pharmaceutical companies now fund much of the continuing medical education that doctors rely on to stay current, using it as a marketing tool rather than objective education. Medical schools increasingly depend on industry funding and often have faculty with extensive industry ties teaching students. Even textbooks are sometimes ghostwritten by industry contractors but published under academic physicians' names.

The corruption extends to residency training, where young doctors learn to rely on industry-sponsored education materials and develop relationships with drug representatives who provide food and other perks. By the time doctors enter practice, they've been thoroughly immersed in an educational system that promotes industry viewpoints and products. The result is a medical profession that has been trained to see healthcare largely through a commercial lens rather than a scientific one.

26. Why has the FDA failed to protect public health?

The FDA has been captured by the very industries it's supposed to regulate, primarily because it now receives most of its funding directly from pharmaceutical companies through "user fees." This has transformed the agency from an independent regulator into an organization that views industry as its client. FDA scientists who try to raise safety concerns about drugs or devices are often ignored or pushed aside, while agency leaders focus on rapid approvals to please their industry funders.

Internal surveys of FDA scientists reveal that many feel pressured to approve drugs despite safety concerns, and those who speak up often face retaliation. The agency has repeatedly failed to act on known safety problems until forced by public outcry or litigation. The FDA's effectiveness is further compromised by inadequate resources for monitoring the global supply chain of drugs and devices, and by a revolving door between agency leadership and industry jobs.

27. How do pharmaceutical companies avoid meaningful regulation?

Pharmaceutical companies employ multiple strategies to avoid effective regulation, starting with massive lobbying efforts that have made them one of the most powerful political forces in Washington. They spend billions on campaign contributions and lobbying to prevent any meaningful reform of drug pricing or regulation. When violations are discovered, they typically settle cases with large fines but no admission of wrongdoing, treating penalties as a cost of doing business while their executives avoid personal accountability.

The companies also manipulate the regulatory process itself, hiding negative data as "trade secrets," using legal maneuvers to extend patents, and exploiting loopholes in approval requirements. They've successfully pushed for faster approval processes with lower evidence standards, while simultaneously working to weaken post-market safety monitoring. When problems are discovered, they often blame individual "bad actors" rather than acknowledging systematic issues with their practices.

28. What happened to FDA whistleblowers who tried to expose problems?

FDA whistleblowers who attempted to expose safety problems or industry influence have faced severe retaliation. Scientists who raised concerns about drug safety were often reassigned, isolated, or forced out of their positions. Some reported threats to their careers and even their families. The agency developed formal policies that made speaking out about problems grounds for termination. Internal surveys showed that a fifth of FDA scientists reported being pressured to approve drugs despite safety concerns.

One particularly striking case involved Ronald Kavanagh, an FDA pharmacist who reviewed medications for a decade. He reported being threatened, having his work undermined, and being excluded from meetings when he raised safety concerns about drugs. When he tried to document problems, he found evidence of data manipulation and possible insider trading by FDA management. His experience exemplifies how the agency systematically silences internal critics to maintain good relationships with industry.

29. How do companies use legal settlements to avoid real change?

Pharmaceutical companies treat massive legal settlements as simply another business expense rather than a deterrent to misconduct. Even billion-dollar settlements represent only a small fraction of the profits they make from illegal practices. For example, GlaxoSmithKline's record $3 billion settlement in 2012 amounted to less than a single year's profits from the drugs involved. Companies factor these penalties into their business models while continuing the same practices that led to the settlements.

Most importantly, settlements allow companies to avoid criminal prosecution of executives and prevent full public disclosure of their misconduct. They typically include no admission of wrongdoing and allow companies to keep selling their products. The settlements often include confidentiality provisions that prevent the public from learning the full extent of the problems. This system has created a situation where companies view occasional large settlements as just another cost of doing business rather than an incentive for reform.

30. What regulatory reforms are proposed?

Fundamental reforms are needed to restore integrity to healthcare regulation. These include eliminating direct industry funding of the FDA through user fees and dramatically increasing the agency's independent funding and enforcement powers. Criminal prosecution of executives responsible for fraud or safety violations, rather than just corporate fines, is essential. Patent laws need reform to prevent abuse and encourage true innovation rather than minor modifications of existing drugs.

Other proposed reforms include mandatory registration of all clinical trials with full data disclosure, elimination of industry influence on medical education and practice guidelines, and strict limits on marketing practices. Some advocate for treating healthcare as a public utility with regulated prices rather than a profit-driven industry. Most fundamentally, the entire system of allowing profit-driven corporations to control essential healthcare needs careful examination and potential restructuring to prioritize public health over private profit.

31. How did the opioid crisis develop and who was responsible?

The opioid crisis emerged primarily through the calculated marketing efforts of Purdue Pharma, which introduced OxyContin in the 1990s and deliberately promoted it as non-addictive and safe for chronic pain. The company orchestrated a massive campaign to change how doctors viewed opioids, spending millions on physician education programs that downplayed addiction risks. They targeted doctors in poverty-stricken areas, provided free samples, and paid physicians to promote their message that pain was undertreated and OxyContin was the solution.

The devastation that followed was unprecedented - by 2019, opioids were killing approximately 50,000 Americans annually, surpassing annual deaths from car accidents or breast cancer. When prescription supplies eventually tightened, many addicted patients turned to cheaper heroin. Purdue finally faced consequences in 2019 when lawsuits forced them into bankruptcy, but not before the Sackler family, who owned Purdue, extracted over $10 billion in profits. Other companies, including major distributors like McKesson and Cardinal Health, also played crucial roles by flooding communities with pills while ignoring obvious signs of abuse.

32. What are the real risks of antidepressant medications?

Antidepressant medications carry far greater risks than most patients are told, including potential suicide and violence, especially in the first weeks of use. The SSRIstories.org database contains thousands of documented cases of violence, suicide, and homicide linked to these drugs. The manufacturers knew about these risks from early trials but deliberately concealed the data. When patients try to stop taking these medications, many experience severe withdrawal effects that can last months or even years, a fact that was also hidden by drug companies.

Perhaps most disturbing is that studies show these drugs barely outperform placebos for most patients while creating physical dependence and potential long-term health problems. Despite this, one in six Americans now takes these medications, with many staying on them indefinitely because doctors aren't trained in how to help patients stop. The drugs can cause emotional numbness, sexual dysfunction, and weight gain, while their long-term effects on brain function remain poorly understood. Yet the massive marketing machine behind these medications continues to promote them as safe and effective.

33. Why are stimulant medications so widely prescribed?

Stimulant medications like Adderall and Ritalin represent another triumph of marketing over medicine. Through aggressive disease mongering, pharmaceutical companies have convinced doctors and the public that normal childhood behaviors, particularly in boys, represent a disease requiring medication. The diagnosis of ADHD has expanded to include 9.4% of American children, with half receiving medication. The industry then successfully expanded the market to adults, promoting the idea that common experiences like distraction or disorganization require chemical treatment.

These medications are chemically similar to methamphetamine and can cause significant harm, including growth suppression in children and potential brain changes. Studies show long-term use often leads to worse outcomes, yet prescriptions continue to soar. Most disturbing is the trend of medicating very young children, including toddlers under two. The drugs have become so commonplace that many college students now feel they need them to compete academically, creating a massive black market on campuses.

34. What's wrong with current cancer screening programs?

Current cancer screening programs often cause more harm than good by detecting many slow-growing cancers that would never have caused problems while subjecting patients to unnecessary procedures and treatments. Mammography screening, for example, has never been shown to improve overall survival rates despite decades of widespread use. Instead, it leads to overdiagnosis and overtreatment, with many women undergoing surgery, radiation, and chemotherapy for cancers that would never have threatened their lives.

Similarly, PSA screening for prostate cancer and routine colonoscopy for average-risk individuals have failed to demonstrate meaningful benefits in overall survival while generating enormous costs and complications from unnecessary interventions. The problem is compounded by financial incentives that encourage aggressive screening and treatment regardless of benefit. The cancer screening industry has become a massive profit center that survives by promoting fear while ignoring evidence that many of its practices don't actually help patients live longer.

35. How effective are preventive medical interventions?

Most preventive medical interventions, particularly those involving medications and screening tests, have proven far less effective than commonly believed. Statins for primary prevention of heart disease, for example, show no meaningful impact on overall survival despite being prescribed to millions of people. Blood pressure medications prescribed for mild hypertension similarly show little benefit for most patients. The concept of "preventive medicine" has largely become a marketing tool to sell drugs and procedures to healthy people.

The most effective preventive measures are actually lifestyle-based - proper diet, regular exercise, adequate sleep, and stress management. However, these approaches receive little attention or promotion because they don't generate profits. Instead, the healthcare system promotes an endless series of tests, screenings, and medications that create the illusion of prevention while primarily serving to generate revenue and often causing direct harm through overdiagnosis and overtreatment.

36. How do hospitals manipulate billing?

Hospitals employ sophisticated billing strategies to maximize revenue, starting with their "chargemaster" - a list of inflated prices for every service and supply. These prices bear no relation to actual costs, with simple items like Tylenol sometimes marked up 100 times or more. Hospitals also add facility fees, which can multiply the cost of simple procedures many times over. They frequently use out-of-network providers within their facilities, leaving even insured patients with massive unexpected bills.

The complexity of hospital billing makes it nearly impossible for patients to understand or challenge charges. Hospitals routinely perform unnecessary tests and procedures to increase revenue, while their coding specialists work to maximize reimbursement through creative categorization of services. Even nonprofit hospitals engage in aggressive collection practices, including lawsuits and property liens against patients unable to pay their inflated bills. The system has become so byzantine that even medical professionals struggle to understand or justify the charges.

37. Why do medical procedures cost so much more in the US?

Medical procedures cost dramatically more in the US primarily because there's no effective mechanism to control prices. Unlike other countries, the US allows providers to charge whatever they want while preventing Medicare, the largest buyer of healthcare services, from negotiating prices. This has created a system where identical procedures often cost many times more than in other developed nations. For example, a hip replacement that costs $40,000 in Belgium might cost $150,000 in the US.

The problem is compounded by a complex web of middlemen, each taking their cut, and by the opacity of pricing that makes it impossible for patients to shop for better values. Hospitals and other providers also use their local monopoly power to demand higher prices from insurance companies, which simply pass the costs on through higher premiums. The result is a system where prices have become completely detached from both costs and value.

38. How does workers' compensation contribute to healthcare waste?

The workers' compensation system exemplifies how third-party payment systems drive up costs and encourage fraud. Studies show that identical injuries cost far more when treated under workers' compensation than regular insurance, partly because providers know they can charge more and partly because the system encourages excessive treatment. The process is further complicated by lawyers who may encourage unnecessary procedures to increase settlement values.

The system's administrative costs are staggering - up to 30-40% of all spending goes to overhead, legal fees, and administration rather than patient care. Treatment delays are common as claims are disputed, often leading to worse outcomes. Yet despite its high costs, the system often fails to serve injured workers well, with many facing years of delays and denials before receiving needed care. The entire process has become so dysfunctional that it serves primarily to enrich various middlemen rather than help injured workers recover.

39. What role do pharmaceutical benefits managers play?

Pharmaceutical Benefits Managers (PBMs) have evolved from simple claims processors into powerful middlemen who control drug pricing while extracting enormous profits. They negotiate prices with drug companies and pharmacies, but instead of passing savings to patients, they often pocket the difference through various schemes. PBMs create complex formularies that favor expensive drugs with high rebates over cheaper alternatives, driving up costs while increasing their own profits.

The lack of transparency in PBM operations makes it impossible to know how much they're really making on each transaction. They've been accused of numerous deceptive practices, including charging insurers one price for drugs while paying pharmacies a lower amount and keeping the difference. Despite contributing nothing to actual healthcare delivery, PBMs have become some of the most profitable companies in the healthcare sector, adding another layer of unnecessary costs to an already bloated system.

40. How do out-of-network billing practices harm patients?

Out-of-network billing has become a predatory practice that leaves even carefully insured patients with massive unexpected bills. Hospitals frequently allow out-of-network doctors - particularly emergency physicians, anesthesiologists, and radiologists - to treat their patients without warning. These doctors then bill patients at inflated rates, often many times what insurance would pay an in-network provider. Even patients who carefully choose in-network hospitals can face thousands or tens of thousands in surprise bills.

This practice, sometimes called "balance billing," has become so common that it affects about one in five emergency room visits. The doctors involved often work for private equity-owned staffing companies that deliberately remain out of network to maximize profits. Despite widespread recognition that these practices are abusive, effective regulation has been blocked by powerful lobbying interests. The result is that millions of Americans face financial ruin from medical bills even when they have insurance and try to follow all the rules.

41. How is medical research data manipulated?

Medical research data undergoes systematic manipulation through multiple sophisticated techniques designed to generate positive results regardless of reality. Companies routinely use "data torturing" or "data mining" - analyzing data repeatedly in different ways until finding something that appears statistically significant. With large studies examining multiple variables, random correlations are inevitable. The companies then present these chance findings as meaningful discoveries while burying negative results.

The manipulation extends to every aspect of study design and execution. Researchers select which patients to include or exclude, choose inappropriate comparison groups, stop trials early if results look favorable, and use surrogate endpoints instead of meaningful outcomes like survival. When negative results emerge, they're often classified as "trade secrets" and never published. The result is a medical literature that presents a distorted picture of reality, making ineffective treatments appear beneficial while hiding their risks.

42. Why are medical journal publications unreliable?

Medical journals have become marketing tools for the pharmaceutical industry rather than sources of objective scientific information. Up to 70% of their revenue comes from drug company advertising and bulk purchases of reprints used for marketing. This financial dependence has led journals to routinely publish ghostwritten articles promoting industry products while rarely questioning industry claims. Many studies are designed, conducted, analyzed, and written by company employees or contractors, then published under academic physicians' names to provide credibility.

Even the most prestigious journals like the New England Journal of Medicine and The Lancet have admitted their content has been compromised by industry influence. Their former editors have publicly stated that the medical literature can no longer be trusted. Negative studies often go unpublished, while positive results are published multiple times in different forms, creating a false impression of consistency. The peer review process provides little protection since most reviewers have their own industry ties.

43. How do statistics get misused in medical research?

Statistics are routinely misused to make meaningless differences appear significant and dangerous treatments seem safe. One common technique is reporting relative risk reduction rather than absolute risk reduction - for example, saying a treatment "cuts risk by 50%" when the absolute reduction is tiny, perhaps from 2% to 1%. Companies also manipulate the baseline groups used for comparison, cherry-pick data points, and use various statistical tricks to manufacture positive results while hiding negative findings.

Another deceptive practice involves conducting multiple analyses until finding something statistically significant, then presenting this as if it were the primary planned analysis. Studies are often designed with inadequate power to detect adverse effects, allowing companies to claim "no evidence of harm" when in reality the studies simply weren't capable of finding problems. The complexity of modern statistical analysis makes it difficult for even trained physicians to spot these manipulations.

44. What's wrong with surrogate endpoints in research?

Surrogate endpoints - measuring things like blood pressure or cholesterol levels rather than meaningful outcomes like survival - have become a major tool for making ineffective treatments appear beneficial. While these measurements might seem logical, many treatments that improve surrogate endpoints don't actually help patients live longer or better. For example, diabetes drugs that lower blood sugar have sometimes been found to increase rather than decrease mortality, despite their apparent benefits on the surrogate endpoint of blood sugar control.

The FDA now frequently approves drugs based solely on surrogate endpoints, particularly in cancer treatment where "progression-free survival" has replaced actual survival as the standard for approval. This allows companies to market expensive drugs that may not help patients live longer or better. The focus on surrogate endpoints also diverts attention from more meaningful measures of benefit and harm, while creating the illusion of progress where none may exist.

45. How are electronic medical records misused?

Electronic medical records (EMRs) have evolved from a potential tool for improving patient care into a mechanism for maximizing billing and protecting against lawsuits. Doctors now spend more time interacting with computers than with patients, forced to click through endless boxes and enter vast amounts of often irrelevant information to satisfy billing requirements. The systems are deliberately designed to facilitate "upcoding" - documenting visits in ways that justify higher charges regardless of medical necessity.

The documentation requirements have become so burdensome that many doctors hire scribes to handle the computer work or spend hours after clinic completing records. The resulting documentation is often bloated with copied and pasted text and irrelevant information included solely for billing purposes. Rather than improving communication and coordination of care, EMRs have largely become a tool for extracting maximum revenue from the healthcare system while actually reducing the time doctors can spend with patients.

46. What specific reforms are needed to fix healthcare?

Healthcare reform requires fundamental changes to eliminate corruption and realign incentives toward patient benefit rather than profit. The essential first step is criminalizing practices that are currently treated as normal business operations - disease mongering, scientific misconduct, data concealment, and using healthcare dollars for lobbying or marketing. The patent system, which enables artificial monopolies and price gouging, needs complete restructuring or elimination. Additionally, conflicts of interest must be prosecuted as criminal acts, similar to insider trading in financial markets.

The current fee-for-service model must be replaced with systems that reward good outcomes rather than volume of services. One promising approach is following the Kaiser Permanente model, where insurance, hospitals, and physicians are integrated into a coordinated system focused on cost-effective care. Funding should be based on actuarial healthcare costs per year of life rather than paying for individual procedures. Finally, ineffective treatments identified through proper scientific study must be systematically defunded, regardless of their profitability.

47. How can patients protect themselves in the current system?

Patients must approach healthcare with informed skepticism while understanding that about half of current medical treatments either don't work or cause more harm than good. The first line of defense is questioning everything - particularly new diagnoses that require long-term medication or invasive procedures. Patients should research thoroughly, get multiple opinions, and never feel pressured into immediate decisions unless facing a true emergency. It's critical to understand that many standard screening tests and preventive medications offer little or no benefit while carrying significant risks.

For hospital care, patients need to be particularly vigilant about billing practices and out-of-network providers. They should document everything, question every charge, and never sign financial responsibility forms without modification. When considering any treatment, patients should ask about absolute risk reduction rather than relative risk statistics, and always consider the option of doing nothing. Most importantly, patients should focus on lifestyle factors that promote health rather than relying on medical interventions that often prove futile or harmful.

48. What role should government play in healthcare reform?

Government must fundamentally shift from enabling industry corruption to protecting public health through meaningful regulation and enforcement. This requires eliminating direct industry funding of the FDA through user fees and dramatically increasing the agency's independent funding and enforcement powers. Criminal prosecution of executives responsible for fraud or safety violations must replace the current system of treating corporate crimes as mere business expenses. Patent laws need complete reform to encourage true innovation rather than minor modifications of existing drugs.

However, simply moving to a single-payer system without addressing underlying corruption would likely make things worse. Government's role should focus on creating proper incentives and enforcing real consequences for misconduct while eliminating conflicts of interest throughout the system. This includes banning industry influence on medical education, research, and practice guidelines. Most fundamentally, the entire concept of allowing profit-driven corporations to control essential healthcare needs careful examination and potential restructuring.

49. How can conflicts of interest be eliminated?

Eliminating conflicts of interest requires treating them as seriously as other forms of financial fraud. All payments from industry to physicians, researchers, and medical organizations must be banned rather than just disclosed. Medical education at all levels must be funded independently of industry influence. Journal editors and guideline authors must have no financial ties to companies whose products they evaluate. Research should be funded through independent entities rather than directly by companies with financial interests in the outcomes.

The entire system of allowing companies to control both the research and marketing of medical products needs restructuring. One approach would be creating an independent institute to conduct all medical research using public funding, with no direct industry involvement. Similarly, medical education should be funded entirely through public sources or professional societies with strict conflict-of-interest policies. Most importantly, the cultural acceptance of industry influence in medicine must change through consistent enforcement of strict ethical standards.

50. What would an ideal healthcare system look like?

An ideal healthcare system would prioritize patient benefit over profit while eliminating current perverse incentives. It would feature salaried physicians working in integrated systems like Kaiser Permanente, where insurance, hospitals, and providers coordinate care with aligned incentives. All medical research would be conducted independently of industry influence, with complete transparency and data sharing. New treatments would require proof of meaningful benefit in properly designed trials before approval, with ongoing monitoring of real-world outcomes.

The system would focus on evidence-based treatments while systematically eliminating ineffective interventions regardless of their profitability. Prevention would emphasize lifestyle factors rather than medications and screening tests of dubious value. Most importantly, the entire healthcare enterprise would be treated as a public service rather than a profit center, with appropriate regulation and oversight to ensure that resources are used effectively to improve public health rather than corporate profits.

I appreciate you being here.

If you've found the content interesting, useful and maybe even helpful, please consider supporting it through a small paid subscription. While everything here is free, your paid subscription is important as it helps in covering some of the operational costs and supports the continuation of this independent research and journalism work. It also helps keep it free for those that cannot afford to pay.

Please make full use of the Free Libraries.

Unbekoming Interview Library: Great interviews across a spectrum of important topics.

Unbekoming Book Summary Library: Concise summaries of important books.

Stories

I'm always in search of good stories, people with valuable expertise and helpful books. Please don't hesitate to get in touch at unbekoming@outlook.com

For COVID vaccine injury

Consider the FLCCC Post-Vaccine Treatment as a resource.

Baseline Human Health

Watch and share this profound 21-minute video to understand and appreciate what health looks like without vaccination.